CytRx Corp Executives
CYTRDelisted Stock | USD 0.18 0.02 12.50% |
CytRx Corp employs about 3 people. The company is managed by 23 executives with a total tenure of roughly 168 years, averaging almost 7.0 years of service per executive, having 0.13 employees per reported executive. Discussion of CytRx Corp's management performance can provide insight into the enterprise performance.
Steven Kriegsman Chairman Chairman, CEO and Pres |
Douglas Wieland President Senior Vice President - Drug Development |
CytRx |
CytRx Corp Management Team Effectiveness
The company has return on total asset (ROA) of (0.52) % which means that it has lost $0.52 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.9189) %, meaning that it created substantial loss on money invested by shareholders. CytRx Corp's management efficiency ratios could be used to measure how well CytRx Corp manages its routine affairs as well as how well it operates its assets and liabilities.CytRx Corp Workforce Comparison
CytRx Corp is number one stock in number of employees category among related companies. The total workforce of Health Care industry is currently estimated at about 144,800. CytRx Corp adds roughly 3.0 in number of employees claiming only tiny portion of equities under Health Care industry.
CytRx Corp Notable Stakeholders
A CytRx Corp stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as CytRx Corp often face trade-offs trying to please all of them. CytRx Corp's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting CytRx Corp's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Steven Kriegsman | Chairman, CEO and Pres | Profile | |
Douglas Wieland | Senior Vice President - Drug Development | Profile | |
Daniel Levitt | Executive Vice President Chief Medical Officer | Profile | |
Eric Curtis | President COO | Profile | |
John Caloz | CFO, Chief Accounting Officer and Treasurer | Profile | |
Benjamin Levin | Sr. VP of Legal Affairs, General Counsel and Corporate Secretary | Profile | |
Louis Ignarro | Independent Director | Profile | |
Cheryl Cohen | Director | Profile | |
Joel Caldwell | Director | Profile | |
Eric Selter | Independent Director | Profile | |
Earl Brien | Director | Profile | |
Anita Chawla | Director | Profile | |
Joseph Rubinfeld | Independent Director | Profile | |
David Haen | VP of Bus. Devel. and Investor Relations | Profile | |
Terri Stevens | Chief Officer | Profile | |
Felix Kratz | Drug VP | Profile | |
Michelle Carroll | IR Contact Officer | Profile | |
Cristina Newman | Co Sec | Profile | |
Molly Poarch | Global Communications | Profile | |
Olivia Ware | Chief Commercial Officer | Profile | |
Shanta Chawla | Senior Executive Officer - Drug Development | Profile | |
Molly Painter | Pres Operations | Profile | |
Stephen Snowdy | Chief Officer | Profile |
About CytRx Corp Management Performance
The success or failure of an entity such as CytRx Corp often depends on how effective the management is. CytRx Corp management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of CytRx management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the CytRx management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California. CYTRX CORP operates under Biotechnology classification in the United States and is traded on PNK Exchange. It employs 3 people.
The data published in CytRx Corp's official financial statements usually reflect CytRx Corp's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of CytRx Corp. For example, before you start analyzing numbers published by CytRx accountants, it's critical to develop an understanding of what CytRx Corp's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of CytRx Corp's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, CytRx Corp's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in CytRx Corp's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of CytRx Corp. Please utilize our Beneish M Score to check the likelihood of CytRx Corp's management manipulating its earnings.
CytRx Corp Workforce Analysis
Traditionally, organizations such as CytRx Corp use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare CytRx Corp within its industry.CytRx Corp Manpower Efficiency
Return on CytRx Corp Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Loss Per Employee | 4.4M | |
Net Loss Per Executive | 572.9K | |
Working Capital Per Employee | 13.8M | |
Working Capital Per Executive | 1.8M |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Other Consideration for investing in CytRx OTC Stock
If you are still planning to invest in CytRx Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the CytRx Corp's history and understand the potential risks before investing.
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
FinTech Suite Use AI to screen and filter profitable investment opportunities |